This could be a very interesting feature of D6 because its potentiality to both inhibit NF-κB and, at the same time, rescue p53 signalling could be exploited either for direct therapeutic interventions against cancer, but also in combined therapies in order to sensitize resistant cancer cells to chemotherapeutic agents that can stimulate apoptosis by inducing DNA damages and triggering p53 apoptotic signals. The gene discussed is NFKB1; the disease is cancer.